Vanguard Personalized Indexing Management
CTMX icon

Vanguard Personalized Indexing Management’s CytomX Therapeutics CTMX Stock Holding History

Vanguard Personalized Indexing Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$98.3K Sell
26,219
-546
-2% -$2.08K ﹤0.01% 2058
2026
Q1 		$126K Hold
26,765
– – ﹤0.01% 1920
2025
Q4 		$114K Sell
26,765
-174
-0.6% -$661 ﹤0.01% 1795
2025
Q3 		$85.9K Sell
26,939
-2,027
-7% -$4.57K ﹤0.01% 1843
2025
Q2 		$65.8K Buy
28,966
+11,258
+64% +$18.1K ﹤0.01% 1791
2025
Q1 		$11.3K Sell
17,708
-19,284
-52% -$15K ﹤0.01% 1821
2024
Q4 		$38.1K Buy
+36,992
New +$39.8K ﹤0.01% 1723

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Personalized Indexing Management's CTMX Position: Q2 2026 in Review

Vanguard Personalized Indexing Management reduced its CytomX Therapeutics (CTMX) stake by 2% in Q2 2026, selling an estimated $2.08K and leaving 26,219 shares worth $98.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2058.

Vanguard Personalized Indexing Management first reported a position in CTMX in Q4 2024 and has held it in 7 quarters since. The position peaked at $126K in Q1 2026. 179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • Vanguard Personalized Indexing Management held 26,219 shares of CytomX Therapeutics worth $98.3K as of Q2 2026.
  • Vanguard Personalized Indexing Management sold 546 CytomX Therapeutics shares in Q2 2026, an estimated $2.08K.
  • CytomX Therapeutics made up ﹤0.01% of Vanguard Personalized Indexing Management's portfolio in Q2 2026, its #2058 holding.
  • Vanguard Personalized Indexing Management first reported a position in CytomX Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Vanguard Personalized Indexing Management's CytomX Therapeutics position peaked at $126K in Q1 2026.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Vanguard Personalized Indexing Management's 13F filing for Q2 2026, filed 11 Aug 2026.